
Editas Medicine (EDIT) Stock
Clinical stage developer of CRISPR gene therapies. Here's the price, business snapshot, and what's worth knowing about Editas Medicine in November 2026.
Editas Medicine (EDIT) is a clinical-stage biotechnology company focused on developing gene-editing therapies using CRISPR-based technologies. The firm aims to correct disease-causing genetic variants for rare and common disorders, with a pipeline that includes in‑vivo and ex‑vivo programmes. As of the given market data, Editas is a small-cap company (market cap ~ $349m), which often means higher share-price volatility and greater sensitivity to clinical and funding news. Key points for investors: clinical-trial results, regulatory decisions, partnership announcements and financing plans can materially affect the stock. There is the potential for significant upside if trials succeed, but also a meaningful risk of setbacks, delays and dilution. This summary is for educational purposes only and not personal investment advice; always consider your risk tolerance, time horizon and consult a qualified adviser before making decisions.
Why You’ll Want to Watch This Stock
Clinical-stage Pipeline
Several programmes are in or approaching clinical evaluation, so trial readouts can be major catalysts — though outcomes can also disappoint.
Catalysts and Risks
Near-term catalysts include study results and partnerships; balance this with regulatory uncertainty and potential dilution from fundraising.
Technology Potential
CRISPR-based approaches aim to address genetic disease at the source, offering transformative potential, but commercial and safety hurdles remain.